viewBiocept Inc

Biocept wins patent in Australia for its Primer-Switch technology

The patent provides intellectual property protection for the technology used for ctDNA analysis

Biocept Inc - Biocept wins patent in Australia for its Primer-Switch technology
This is the first issued patent for Biocept's Primer-Switch technology

Biocept Inc (NASDAQ:BIOC), a provider of liquid biopsy tests for doctors and their patients with cancer, revealed it has won a patent in Australia.

The award provides intellectual property protection for Biocept's Primer-Switch technology that is useful for ctDNA analysis using real-time PCR and associated analysis methods, including next-generation sequencing (NGS).

"The issuance of this patent expands Biocept's intellectual property protection for rare mutation detection," said Lyle Arnold, chief scientific officer, in a statement. 

"The Primer-Switch is a method for the detection of rare genetic events and is an addition to our Switch-Blocker technology, which is routinely used with our ctDNA Target Selector assays,” he added. 

READ: Biocept unveils second contract for its assay services with California independent physician association

Arnold noted that this is the first issued patent for the Primer-Switch technology, which the San Diego-based company believes will achieve eventual worldwide patent protection. 

“It provides another tool in Biocept's toolkit of methods to inform on biomarkers to aid physician decision-making in the treatment of cancer patients," he added. 

The recently issued Australian patent is another method for specifically enriching patient specimens for oncogene mutations of interest, the company explained.

The Primer-Switch technology is used as part of PCR reactions, which are core to the most commonly used method of amplification in diagnostic assays. Primer-Switch methodology has the potential to find wide use in PCR reactions, especially where the detection of rare genetic events is needed, or in cases where more precise PCR amplifications are desired.

"The expansion of our intellectual property continues the global validation of our technology and further positions Biocept as a provider of cutting-edge approaches for the detection of rare genetic events using blood and other fluids," said CEO Michael Nall. 

"We continue to develop innovative products and technologies such as Primer-Switch to stay ahead of the curve in liquid biopsy technology."

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: Biocept Inc

Price: 4.86 USD

Market: NASDAQ
Market Cap: $65.11 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...


Biocept announces Highmark has made a positive coverage determination on...

Biocept (Nasdaq: BIOC) CEO Michael Nall joined Steve Darling from Proactive with news the company has received positive news from Highmark, America’s fourth-largest Blue Cross Shield affiliate. That news being Biocept's Target Selector liquid biopsy assays have been accepted for medical coverage...

on 23/9/20

2 min read